Federal News
FDA Advances National Priority Voucher Program
March 21, 2026
The U.S. Food and Drug Administration (FDA) has approved a higher dose (7.2 mg) of Novo Nordisk's Wegovy (semaglutide) injection for weight loss under its National Priority Voucher (CNPV) pilot program, marking the fourth product approved through this expedited review pathway since the program's launch in June 2025. This program aims to accelerate the review of drugs and biologics that address strategic national health priorities, with 18 vouchers awarded and four approvals granted to date, significantly reducing review times to as few as 54 days. The FDA has scheduled a public meeting on June 12, 2026, at its White Oak campus in Silver Spring, Maryland, to solicit stakeholder feedback on the program's implementation and future direction.
- Why this matters: Procurement professionals and contractors should note the FDA's increasing use of expedited pathways to accelerate access to critical therapies, which may influence contract timelines and vendor engagement strategies.
- The program's success in reducing review times indicates potential for faster market entry for qualifying pharmaceutical products, impacting supply chain and procurement planning.
- Stakeholders can participate in the June 12 public meeting to provide input on the program, potentially shaping future procurement priorities and regulatory frameworks.
- Pharmaceutical companies developing drugs aligned with national health priorities may find enhanced opportunities through this voucher program, emphasizing the importance of aligning product development with FDA strategic goals.
The new FDA is moving with unprecedented efficiency on products that advance national priorities.
— Martin Makary, M.D., M.P.H., FDA Commissioner
National priority vouchers are a game changer for patients waiting for life-changing therapies.
— Marty Makary, M.D., M.P.H., FDA Commissioner
Every time they refuse to use accelerated approval pathways that Congress permitted for the rarest conditions, we lose another child.
— Mark Dant
Agencies
U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, U.S. Senate, Centers for Disease Control and Prevention
Vendors
Novo Nordisk, Eli Lilly, Ultragenyx, Regenxbio, Denali Therapeutics
Locations
Sources
- FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide | FDA · FDA · Mar 20
- FDA to seek public input on drug-priority program - POLITICO · Politico · Mar 21
- FDA Schedules Public Meeting on the Commissionerβs National Priority Voucher Pilot Program | FDA · FDA · Mar 21